AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24065423 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia with leukocyte reduction filters
Number of subjects: 40
Study 24065423 — intervention group
Group type: COMPARATOR
Intervention: Blood cardioplegia without leukocyte reduction filters (Group II)
Number of subjects: 40
Study 21849601 — intervention group
Group type: EXPERIMENTAL
Intervention: partially hydrolyzed whey (pHF-W)
Number of subjects: 1840
Study 21849601 — intervention group
Group type: EXPERIMENTAL
Intervention: extensively hydrolyzed whey (eHF-W)
Number of subjects: 1840
Study 21849601 — intervention group
Group type: EXPERIMENTAL
Intervention: extensively hydrolyzed casein (eHF-C)
Number of subjects: 1840
Study 21849601 — intervention group
Group type: EXPERIMENTAL
Intervention: cow-milk formula (CMF)
Number of subjects: 1840
Study 21849601 — intervention group
Group type: EXPERIMENTAL
Intervention: breastfeeding (BF)
Number of subjects: 1840
Study 19756742 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline treatment for 6 weeks
Number of subjects: 68
Study 19756742 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline treatment
Number of subjects: 68
Study 18024838 — intervention group
Group type: EXPERIMENTAL
Intervention: Iceman
Number of subjects: 4
Study 18024838 — intervention group
Group type: EXPERIMENTAL
Intervention: EBIce
Number of subjects: 4
Study 18024838 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle Cryo/Cuff
Number of subjects: 4
Study 18024838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy devices (all)
Number of subjects: 4
Study 15375524 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU + LV for 6 months
Number of subjects: 150
Study 15375524 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU + LVZ for 12 months
Number of subjects: 150
Study 11478761 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron polymaltose complex (IPC)
Number of subjects: 100
Study 11478761 — intervention group
Group type: COMPARATOR
Intervention: Ferrous fumarate
Number of subjects: 100
Study 9596318 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine 3 microg/kg/min
Number of subjects: 27
Study 9596318 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine 5 microg/kg/min
Number of subjects: 27
Study 9596318 — intervention group
Group type: EXPERIMENTAL
Intervention: Three CO measurements for VO2 and DO2
Number of subjects: 27
Study 9596318 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighting the slope to the observed change in DO2
Number of subjects: 27
Study 7835264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraumbilical infusion through a mucus aspiration catheter
Number of subjects: 21
Study 7835264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraumbilical infusion by an 18 gauge needle (direct injection)
Number of subjects: 21
Study 2974713 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 3.75‐15 micrograms kg‐1 with nitrous oxide and midazolam
Number of subjects: 30
Study 29863378 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical neural network model with top‐down and lateral synaptic connections, multiple synaptic contacts, and spike-timing-dependent plasticity.
Number of subjects: 0
Study 29863378 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurons representing binding relationships between low-level and high-level visual features through visually guided learning.
Number of subjects: 0
Study 26973347 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rivaroxaban OD for 45 days
Number of subjects: 0
Study 26973347 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg fondaparinux OD for 45 days
Number of subjects: 0
Study 24925924 — intervention group
Group type: EXPERIMENTAL
Intervention: New diagnosis of COPD (screening)
Number of subjects: 386
Study 22641239 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months for 36 months
Number of subjects: 734
Study 22641239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 734
Study 20554607 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased subretinal tissue volume
Number of subjects: 122
Study 20554607 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal fluid (SRF) volume
Number of subjects: 122
Study 20554607 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased retinal thickness at the foveal center
Number of subjects: 122
Study 19029470 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 112
Study 19029470 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drugs
Number of subjects: 112
Study 15753273 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone (0.6 mg/kg, max 10 mg)
Number of subjects: 150
Study 15753273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 12531351 — intervention group
Group type: EXPERIMENTAL
Intervention: Outer membrane vesicle (OMV) vaccines
Number of subjects: 172000
Study 11240955 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg
Number of subjects: 14
Study 11240955 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine 50 mg
Number of subjects: 14
Study 9271963 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth center care
Number of subjects: 1860
Study 9271963 — intervention group
Group type: COMPARATOR
Intervention: Standard maternity care
Number of subjects: 1860
Study 8516659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg three times daily
Number of subjects: 11
Study 8516659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3565812 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (0.005, 0.01, 0.02 or 0.05 mg/kg)
Number of subjects: 120
Study 3565812 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (0.02, 0.04, 0.1, or 0.2 mg/kg)
Number of subjects: 120
Study 3565812 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium (0.1, 0.2, 0.4 or 1 mg/kg)
Number of subjects: 120
Study 31273506 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan formulation (study cream, S)
Number of subjects: 30
Study 31273506 — intervention group
Group type: COMPARATOR
Intervention: Control cream (placebo, P)
Number of subjects: 30
Study 31273506 — intervention group
Group type: COMPARATOR
Intervention: Independent panel assessment
Number of subjects: 30
Study 28943477 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention (including self-efficacy component)
Number of subjects: 275
Study 28943477 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 275
Study 27879359 — intervention group
Group type: EXPERIMENTAL
Intervention: DECIDE Self‐Study
Number of subjects: 182
Study 27879359 — intervention group
Group type: EXPERIMENTAL
Intervention: DECIDE Individual
Number of subjects: 182
Study 27879359 — intervention group
Group type: EXPERIMENTAL
Intervention: DECIDE Group
Number of subjects: 182
Study 27879359 — intervention group
Group type: COMPARATOR
Intervention: Enhanced UC
Number of subjects: 182
Study 25567120 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS combined with rPNS
Number of subjects: 20
Study 25567120 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS combined with rPNS
Number of subjects: 20
Study 22796108 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil, 200 mg, once daily
Number of subjects: 61
Study 22796108 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram, 20 mg, once daily
Number of subjects: 61
Study 22796108 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil + Escitalopram, once daily
Number of subjects: 61
Study 22796108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 20871178 — intervention group
Group type: EXPERIMENTAL
Intervention: Office noise
Number of subjects: 60
Study 20871178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mozart's music
Number of subjects: 60
Study 17899310 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation (100 mJ/pulse; 15 Hz; 1.5 W, 60 s, 141.5 J/cm(2))
Number of subjects: 17
Study 17899310 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 17
Study 16798442 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with intermittent 10‐mL boluses of 0.125% levobupivacaine into the epidural space and physiologic saline into the surgical wound
Number of subjects: 40
Study 16798442 — intervention group
Group type: COMPARATOR
Intervention: Incisional analgesia with intermittent 10‐mL boluses of 0.25% levobupivacaine into the wound and epidural saline
Number of subjects: 40
Study 16798442 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 14725383 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% zinc citrate, 0.3% Triclosan dentifrice
Number of subjects: 40
Study 14725383 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 40
Study 10762286 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinagolide (0.075 to 0.6 mg/day)
Number of subjects: 20
Study 10762286 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 to 3 mg/week)
Number of subjects: 20
Study 10762286 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinagolide and Cabergoline
Number of subjects: 20
Study 9101848 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 963
Study 9101848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 963
Study 30669022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 21
Study 30669022 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 21
Study 29717291 — intervention group
Group type: EXPERIMENTAL
Intervention: Diathermy
Number of subjects: 65
Study 29717291 — intervention group
Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 65
Study 26716357 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-inhalation nebulizer (AKITA)
Number of subjects: 10
Study 26716357 — intervention group
Group type: COMPARATOR
Intervention: Conventional nebulizer (PARI-LC Plus)
Number of subjects: 10
Study 24698199 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour hemodialysis (HD4)
Number of subjects: 13
Study 24698199 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour hemodiafiltration (HDF4)
Number of subjects: 13
Study 24698199 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hour hemodialysis (HD8)
Number of subjects: 13
Study 24698199 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hour hemodiafiltration (HDF8)
Number of subjects: 13
Study 22759069 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT (regenerative injection therapy)
Number of subjects: 36
Study 22759069 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy only
Number of subjects: 36
Study 22759069 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT after exercise therapy
Number of subjects: 36
Study 22759069 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (after 36 weeks)
Number of subjects: 36
Study 18482589 — intervention group
Group type: EXPERIMENTAL
Intervention: I-FOBT (OC-Sensor)
Number of subjects: 20623
Study 18482589 — intervention group
Group type: COMPARATOR
Intervention: G-FOBT (Hemoccult-II)
Number of subjects: 20623
Study 16518579 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day)
Number of subjects: 200
Study 16518579 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (10 mg/day)
Number of subjects: 200
Study 16518579 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day) and Prednisolone (10 mg/day)
Number of subjects: 200
Study 16518579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 12901730 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nicorandil-induced lesions
Number of subjects: 60
Study 12901730 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical criteria used by physicians
Number of subjects: 60
Study 12901730 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of yellow-based ulceration
Number of subjects: 60
Study 12901730 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear shape of lesions
Number of subjects: 60
Study 12901730 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of inflammatory halo
Number of subjects: 60
Study 11180878 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.9% branched chain amino acid (BCAA) solution
Number of subjects: 30
Study 11180878 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 30
Study 9309356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy
Number of subjects: 39
Study 9309356 — intervention group
Group type: COMPARATOR
Intervention: Exposure
Number of subjects: 39
Study 7828459 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 92
Study 7828459 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 92
Study 7828459 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 92
Study 3518107 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstention from MTX-containing beverages
Number of subjects: 192
Study 3518107 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstention from alcohol
Number of subjects: 192
Study 3518107 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstention from MTX and alcohol
Number of subjects: 192
Study 3518107 — intervention group
Group type: COMPARATOR
Intervention: No dietary advice
Number of subjects: 192
Study 29899395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy with cisplatin (50 mg/m2) and etoposide (100 mg/m2) followed by intravenous chemotherapy
Number of subjects: 215
Study 29899395 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemotherapy alone
Number of subjects: 215
Study 29899395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy with cisplatin and etoposide
Number of subjects: 215
Study 27566745 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tubes (NGT)
Number of subjects: 1217
Study 27566745 — intervention group
Group type: COMPARATOR
Intervention: Poststroke pneumonia (PSP)
Number of subjects: 1217
Study 22956633 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered health coaching (ProActive Heart)
Number of subjects: 430
Study 22956633 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 430
Study 22250141 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 IU of vitamin D supplementation every 4 weeks for 1 year
Number of subjects: 182
Study 22250141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 21190551 — intervention group
Group type: COMPARATOR
Intervention: NDUFV2 gene promoter variants (rs6506640 and rs1156044)
Number of subjects: 529
Study 18237663 — intervention group
Group type: COMPARATOR
Intervention: Intravenous catheter collection technique
Number of subjects: 853
Study 18237663 — intervention group
Group type: EXPERIMENTAL
Intervention: Venipuncture collection technique
Number of subjects: 853
Study 16247245 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Relief gel (3% menthol)
Number of subjects: 2
Study 16247245 — intervention group
Group type: COMPARATOR
Intervention: Ibuleve gel (only ibuprofen)
Number of subjects: 2
Study 14585881 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 24
Study 14585881 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid
Number of subjects: 24
Study 11885174 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA)-cylinder
Number of subjects: 2900
Study 11885174 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-alloy screw
Number of subjects: 2900
Study 11885174 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially pure titanium screw
Number of subjects: 2900
Study 11885174 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated implants
Number of subjects: 2900
Study 11885174 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-HA implants
Number of subjects: 2900
Study 11885174 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-grooved implant
Number of subjects: 2900
Study 8599319 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg beta-carotene supplementation
Number of subjects: 73
Study 8599319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 1568865 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ketanserin, 10 mg given 30 min before test
Number of subjects: 8
Study 1568865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3907687 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulphan
Number of subjects: 726
Study 3907687 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 726
Study 3907687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 726
Study 3907687 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological involvement of resected intrathoracic nodes
Number of subjects: 726
Study 3907687 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological type of the tumour
Number of subjects: 726
Study 30588322 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg every 4 weeks
Number of subjects: 201
Study 30588322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 27631883 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline amino-terminal pro-B type natriuretic peptide (NT-proBNP)
Number of subjects: 108
Study 27631883 — intervention group
Group type: EXPERIMENTAL
Intervention: Edema
Number of subjects: 108
Study 27631883 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent time with NT-proBNP ≥1000 pg/mL (serial measurement)
Number of subjects: 108
Study 25624376 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal colostrum administration (0.2 mL every 3 hours for 3 days)
Number of subjects: 48
Study 22949570 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 390
Study 22949570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 20049961 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rapamycin (2 mg/day for 30 days)
Number of subjects: 80
Study 18509181 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil and irinotecan
Number of subjects: 1628
Study 18509181 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil and oxaliplatin
Number of subjects: 1628
Study 18509181 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil, irinotecan, and oxaliplatin (first-line combination chemotherapy)
Number of subjects: 1628
Study 17043133 — intervention group
Group type: EXPERIMENTAL
Intervention: Creating Opportunities for Parent Empowerment program
Number of subjects: 260
Study 17043133 — intervention group
Group type: COMPARATOR
Intervention: Comparison intervention
Number of subjects: 260
Study 14520110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate (FP, Flonase)
Number of subjects: 16
Study 14520110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 14520110 — intervention group
Group type: COMPARATOR
Intervention: Normal control nasal turbinate tissues
Number of subjects: 16
Study 10878070 — intervention group
Group type: EXPERIMENTAL
Intervention: COBAS HCV MONITOR version 2.0
Number of subjects: 174
Study 10878070 — intervention group
Group type: COMPARATOR
Intervention: AMPLICOR HCV MONITOR version 1.0
Number of subjects: 174
Study 10878070 — intervention group
Group type: EXPERIMENTAL
Intervention: QUANTIPLEX HCV RNA version 2.0
Number of subjects: 174
Study 10437173 — intervention group
Group type: EXPERIMENTAL
Intervention: Wu Zi Yan Zong (WZYZ) fluid
Number of subjects: 0
Study 1441867 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 5‐6 mg/kg
Number of subjects: 30
Study 1441867 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2‐3 mg/kg
Number of subjects: 30
Study 3954815 — intervention group
Group type: EXPERIMENTAL
Intervention: tasuldine
Number of subjects: 15
Study 3954815 — intervention group
Group type: EXPERIMENTAL
Intervention: acetylcysteine
Number of subjects: 15
Study 3954815 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 15
Study 31744637 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective induction at 39 weeks
Number of subjects: 0
Study 31744637 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31644588 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital decision support tool
Number of subjects: 89
Study 31644588 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 89
Study 25731858 — intervention group
Group type: EXPERIMENTAL
Intervention: EPICTM nitinol vascular stent system
Number of subjects: 83
Study 25462598 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination condition
Number of subjects: 59
Study 25462598 — intervention group
Group type: COMPARATOR
Intervention: Distraction condition
Number of subjects: 59
Study 25462598 — intervention group
Group type: COMPARATOR
Intervention: Non-dysphoric ruminating condition
Number of subjects: 59
Study 25462598 — intervention group
Group type: COMPARATOR
Intervention: Non-dysphoric distracting condition
Number of subjects: 59
Study 23757968 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil combined with behavior therapy
Number of subjects: 60
Study 23757968 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil only (control group)
Number of subjects: 60
Study 21907861 — intervention group
Group type: EXPERIMENTAL
Intervention: F(E)NO group
Number of subjects: 220
Study 21907861 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 220
Study 19727663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (dietary restrictions and exercise training)
Number of subjects: 261
Study 16714425 — intervention group
Group type: EXPERIMENTAL
Intervention: 160/12.5 mg valsartan/hydrochlorothiazide (HCTZ)
Number of subjects: 1668
Study 16714425 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 1668
Study 16714425 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan/HCTZ
Number of subjects: 1668
Study 15492306 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized empirical ATP (n=313)
Number of subjects: 634